← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodyJanssenderuxtecan in ovarian cance…Phase 3

infliximab (Remicade, Remicade (infliximab))

Uveitis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#인기#항체+5
임상시험 62상태 ACTIVE
AntibodyRochegovitecan in patients with …Phase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody)

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase3#인기#항체+4
효능 ORR 75%임상시험 61상태 ACTIVE
AntibodyBristol Myers Squibbvedotin after avelumabPhase 2

Opdivo (Nivolumab, Nivolumab (Opdivo))

Solid Tumors · Anaplastic Large Cell Lymphoma, ALK-Posi

#AnaplasticLargeCellLymphomaALK-P#Antibody#Phase2#인기#항체+5
효능 ORR 100%임상시험 61상태 RECRUITING
AntibodyRochegovitecan in patients with …Preclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#인기#항체+4
효능 ORR 46.4%임상시험 60상태 ACTIVE
AntibodyMario Negri Institute for Pharm…Approved

Certolizumab pegol (Certolizumab pegol)

Rheumatoid Arthritis · Crohn's Disease

#CrohnsDisease#Antibody#Approved#인기#항체+4
효능 ORR 5%임상시험 60상태 ACTIVE
AntibodyGlaxoSmithKlinederuxtecan improved objecti…Phase 2

Dostarlimab (Dostarlimab)

Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase2#인기#항체+5
효능 ORR 88%임상시험 60상태 DISCONTINUED
AntibodySun Yat-sen Universityvedotin combined with immun…Phase 3

Serplulimab (Serplulimab)

Colorectal Cancer; Liver Metastases · Solid Tumor Cancer

#SolidTumorCancer#Antibody#Phase3#인기#항체+5
임상시험 60상태 RECRUITING
AntibodyJanssenApproved

Teclistamab (Teclistamab)

Myeloma Multiple; Plasma Cell Leukemia · Myeloma Multiple

#MyelomaMultiple#Antibody#Approved#인기#항체+5
임상시험 60상태 RECRUITING
AntibodyRocheDM1) and trastuzumab deruxt…Preclinical

trastuzumab (Herceptin, Trastuzumab + Pertuzumab)

Solid Tumor; Advanced Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Preclinical#인기#항체+5
효능 ORR 79.5%임상시험 60상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, ipilimumab + nivolumab)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+4
효능 ORR 77.8%임상시험 60상태 RECRUITING
AntibodyRegeneronDemonstratePhase 2

Cemiplimab + Fianlimab [Fixed Dose Combination (FDC, Cemiplimab + Fianlimab [Fixed Dose Combination, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)])

Ovarian Cancer; Fallopian Tube Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#인기#항체+5
효능 ORR 100%임상시험 59상태 RECRUITING
AntibodyUCB PharmaApproved

Certolizumab (Certolizumab)

Psoriasis; Atopic Dermatitis · Chronic Nonbacterial Osteomyelitis

#ChronicNonbacterialOsteomyelitis#Antibody#Approved#인기#항체+5
효능 ORR 5%임상시험 59상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab and nivolumab)

Mesothelioma; Pancreatic Cancer · Uveal Melanoma, Metastatic

#UvealMelanomaMetastatic#Antibody#Phase2#인기#항체+5
효능 ORR 77.8%임상시험 59상태 RECRUITING
AntibodyRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Bevacizumab)

Hepatocellular Carcinoma · Resectable Hepatocellular Carcinoma

#ResectableHepatocellularCarcinom#Antibody#Phase2#인기#항체+5
효능 ORR 50%임상시험 58상태 DISCONTINUED
AntibodyNovartisApproved

Basiliximab (Basiliximab)

Type 1 Diabetes Mellitus · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#Antibody#Approved#인기#항체+4
효능 ORR 10%임상시험 58상태 ACTIVE
AntibodyGenentech, Inc.Phase 2

Ocrelizumab (Ocrelizumab)

Rheumatoid Arthritis · Multiple Sclerosis

#MultipleSclerosis#Antibody#Phase2#인기#항체+5
임상시험 58상태 DISCONTINUED
AntibodyWei-Che KoPhase 3

Canakinumab (Canakinumab)

Skin Inflammation; Allergic Contact Dermatitis · Skin Inflammation

#SkinInflammation#Antibody#Phase3#인기#항체+5
효능 ORR 4.9%임상시험 57상태 RECRUITING
AntibodySanofiApproved

Dupilumab SAR231893 (Dupilumab SAR231893)

Chronic Obstructive Pulmonary Disease · Dermatitis Atopic

#DermatitisAtopic#Antibody#Approved#인기#항체+5
효능 ORR 0.44%임상시험 57상태 ACTIVE
AntibodyPfizerPhase 3

Elotuzumab (Elotuzumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+4
효능 ORR 100%임상시험 57상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab monotherapy)

Advanced Metastatic Cancer; Advanced Prostate Cancer · Genitourinary Cancers

#GenitourinaryCancers#Antibody#Phase2#인기#항체+5
효능 ORR 59%임상시험 57상태 RECRUITING

5 / 92 페이지

← 이전다음 →